CCO Treatment Updates
A New Era for Treatment: Advanced Issues in the Long-Term Management of Chronic HBV
Goals and Challenges in the Treatment of Hepatitis B
|
Module 1 of 3
|
CME Program Director:
Ira M. Jacobson, MD
- Nezam H. Afdhal, MD, FRCPI
|
|
|
 Topics covered include:
- Introduction
- Identification of HBV Patients
- Evaluation of the HBV Patient and Indications for Therapy
- Guidelines for Treatment
- Liver Biopsy and Normal ALT
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the process of identifying and classifying HBV patients, and guidelines for deciding which patients to treat.
- Discuss the key treatment endpoints for patients with chronic hepatitis B.
- Review the major challenges in the long-term treatment of patients with chronic hepatitis B.
|
Clinical Data on Long-Term Treatment of Hepatitis B
|
Module 2 of 3
|
CME Program Director:
Ira M. Jacobson, MD
|
|
Topics covered include:
- Introduction
- Long-Term Treatment with Lamivudine
- Long-term Lamivudine in HBeAg-positive Patients
- Long-Term Lamivudine in Patients with Advanced Disease
- Long-Term Lamivudine Plus Interferon
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recount data outlining the challenges in long-term treatment for chronic hepatitis B.
- Discuss the therapeutic options for HBeAg-positive and HBeAg-negative patients requiring long-term treatment for chronic hepatitis B.
- Review data regarding which patients should receive long-term treatment for chronic hepatitis B.
|
Strategies for Managing Resistance to Nucleoside/Nucleotide Analogues
|
Module 3 of 3
|
CME Program Director:
Ira M. Jacobson, MD
|
|
Topics covered include:
- Introduction
- Treatment Objectives
- HBV Life Cycle
- Mechanisms of Drug Resistance
- Patients With Drug Resistance
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the HBV life cycle, targets for treatment and mechanisms of drug resistance.
- Review the resistance profiles for drugs used for the treatment of chronic hepatitis B.
- Recount recommendations for monitoring and managing drug resistance in chronic hepatitis B infection.
|
Interactive Case Challenges
A 42-year-old man with lamivudine-resistant HBeAg-negative chronic hepatitis B infection
CME Program Director:
Ira M. Jacobson, MD
|
|
 Ira M. Jacobson, MD, presents a case of a 42-year-old man with lamivudine-resistant HBeAg-negative chronic hepatitis B infection. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe data regarding the management of patients with drug-resistant HBV.
- Discuss the various treatment options for patients with HBeAg-negative chronic hepatitis B.
- Recount data regarding treatment duration for patients with HBeAg-negative chronic hepatitis B.
|
A 35-year-old Asian man with previously untreated HBeAg-positive chronic hepatitis B infection
CME Program Director:
Ira M. Jacobson, MD
|
|
Robert G. Gish, MD, presents a case of a 35-year-old Asian man with previously untreated HBeAg-positive chronic hepatitis B infection. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the various therapeutic options for patients with HBeAg-positive chronic hepatitis B.
- Recount data regarding the treatment goals in HBeAg-positive chronic hepatitis B, and the role of viral suppression in treating the disease.
- Describe results evaluating the management of complications associated with HBV infection
|
CCO Slidesets
Goals and Challenges in the Treatment of Hepatitis B
 |
|
Format: Microsoft PowerPoint (.ppt) | File size: 1,069 KB
|
Clinical Data on Long-Term Treatment of Hepatitis B
 |
|
Format: Microsoft PowerPoint (.ppt) | File size: 238 KB
|
Strategies for Managing Resistance to Nucleoside/Nucleotide Analogues
 |
|
Format: Microsoft PowerPoint (.ppt) | File size: 142 KB
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Medical Education Collaborative and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|
|